Purpose
|
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.
|
Characteristics
|
Tradename: SC-65872, YM-974 Source of Compound: synthetic Target: COX inhibitor Receptor: Prostaglandin G/H synthase Status: AU
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
98?%
|
Formula
|
C16H14N2O3S
|
Solubility
|
DMSO 63 mg/mL,Ethanol 18 mg/mL,Water <1 mg="" ml="" <="" td="">
1> |